Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53
1998

VEGF and Nitric Oxide Synthase in Lung Cancer

Sample size: 27 publication Evidence: moderate

Author Information

Author(s): S Ambs, WP Bennett, WG Merriam, MO Ogunfusika, SM Oser, MA Khan, RT Jones, CC Harris

Primary Institution: National Cancer Institute

Hypothesis

Oncogenes and tumor suppressors regulate VEGF expression in lung cancer.

Conclusion

The study found no direct regulation of VEGF by p53 in non-small-cell lung cancer (NSCLC).

Supporting Evidence

  • VEGF was expressed in 50% of squamous cell carcinomas and carcinoids.
  • p53 mutations occurred in 52% of tumors analyzed.
  • Ca2+-dependent NOS activity was significantly reduced in lung carcinomas compared to adjacent non-tumor tissue.

Takeaway

This study looked at how certain genes affect a protein that helps tumors grow new blood vessels in lung cancer, but they didn't find a clear link.

Methodology

The study analyzed VEGF protein expression and mutations in p53 and K-ras in 27 non-small-cell lung cancers.

Limitations

The study did not find correlations between VEGF expression and mutations in p53 or K-ras.

Participant Demographics

The study included 27 patients with various types of non-small-cell lung cancer.

Statistical Information

P-Value

p<0.004

Statistical Significance

p<0.004

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication